Long-term outcomes after severe acute kidney injury in critically ill patients: the SALTO study.
Acute kidney injury
Long-term outcomes
Renal replacement therapy
Worsening renal failure
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
13 Mar 2023
13 Mar 2023
Historique:
received:
25
09
2022
accepted:
07
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
The extent of the consequences of an episode of severe acute kidney injury (AKI) on long-term outcome of critically ill patients remain debated. We conducted a prospective follow-up of patients included in a large multicenter clinical trial of renal replacement therapy (RRT) initiation strategy during severe AKI (the Artificial Kidney Initiation in Kidney Injury, AKIKI) to investigate long-term survival, renal outcome and health related quality of life (HRQOL). We also assessed the influence of RRT initiation strategy on these outcomes. Follow-up of patients extended from 60 days to a median of 3.35 years [interquartile range (IQR), 1.89 to 4.09] after the end of initial study. Of the 619 patients included in the AKIKI trial, 316 survived after 60 days. The overall survival rate at 3 years from inclusion was 39.4% (95% CI 35.4 to 43.4). A total of 46 patients (on the 175 with available data on long-term kidney function) experienced worsening of renal function (WRF) at the time of follow-up [overall incidence of 26%, cumulative incidence at 4 years: 20.6% (CI 95% 13.0 to 28.3)]. Fifteen patients required chronic dialysis (5% of patients who survived after day 90). Among the 226 long-term survivors, 80 (35%) answered the EQ-5D questionnaire. The median index value reported was 0.67 (IQR 0.40 to 1.00) indicating a noticeable alteration of quality of life. Initiation strategy for RRT had no effect on any long-term outcome. Severe AKI in critically ill patients was associated with a high proportion of death within the first 2 months but less so during long-term follow-up. A quarter of long-term survivors experienced a WRF and suffered from a noticeable impairment of quality of life. Renal replacement therapy initiation strategy was not associated with mortality outcome.
Sections du résumé
BACKGROUND
BACKGROUND
The extent of the consequences of an episode of severe acute kidney injury (AKI) on long-term outcome of critically ill patients remain debated. We conducted a prospective follow-up of patients included in a large multicenter clinical trial of renal replacement therapy (RRT) initiation strategy during severe AKI (the Artificial Kidney Initiation in Kidney Injury, AKIKI) to investigate long-term survival, renal outcome and health related quality of life (HRQOL). We also assessed the influence of RRT initiation strategy on these outcomes.
RESULTS
RESULTS
Follow-up of patients extended from 60 days to a median of 3.35 years [interquartile range (IQR), 1.89 to 4.09] after the end of initial study. Of the 619 patients included in the AKIKI trial, 316 survived after 60 days. The overall survival rate at 3 years from inclusion was 39.4% (95% CI 35.4 to 43.4). A total of 46 patients (on the 175 with available data on long-term kidney function) experienced worsening of renal function (WRF) at the time of follow-up [overall incidence of 26%, cumulative incidence at 4 years: 20.6% (CI 95% 13.0 to 28.3)]. Fifteen patients required chronic dialysis (5% of patients who survived after day 90). Among the 226 long-term survivors, 80 (35%) answered the EQ-5D questionnaire. The median index value reported was 0.67 (IQR 0.40 to 1.00) indicating a noticeable alteration of quality of life. Initiation strategy for RRT had no effect on any long-term outcome.
CONCLUSION
CONCLUSIONS
Severe AKI in critically ill patients was associated with a high proportion of death within the first 2 months but less so during long-term follow-up. A quarter of long-term survivors experienced a WRF and suffered from a noticeable impairment of quality of life. Renal replacement therapy initiation strategy was not associated with mortality outcome.
Identifiants
pubmed: 36907976
doi: 10.1186/s13613-023-01108-x
pii: 10.1186/s13613-023-01108-x
pmc: PMC10008759
doi:
Types de publication
Journal Article
Langues
eng
Pagination
18Informations de copyright
© 2023. The Author(s).
Références
Kidney Int. 2012 Mar;81(5):477-85
pubmed: 22157656
J Bone Miner Res. 2014 Mar;29(3):676-84
pubmed: 23929760
Trials. 2015 Apr 17;16:170
pubmed: 25902813
Nephrol Dial Transplant. 2006 Feb;21(2):411-8
pubmed: 16234286
J Am Soc Nephrol. 2018 Mar;29(3):1011-1019
pubmed: 29196304
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Intensive Care Med. 2020 Mar;46(3):513-515
pubmed: 31832745
PLoS One. 2012;7(5):e36388
pubmed: 22574153
Intensive Care Med. 2015 Nov;41(11):1993-5
pubmed: 26362952
N Engl J Med. 2016 Jul 14;375(2):122-33
pubmed: 27181456
Nephron. 1976;16(1):31-41
pubmed: 1244564
Nephrol Dial Transplant. 2018 Dec 1;33(12):2218-2227
pubmed: 29846676
J Am Soc Nephrol. 2010 Feb;21(2):345-52
pubmed: 20019168
Am J Manag Care. 2017 Jun;23(10 Suppl):S163-S172
pubmed: 28978205
Int J Epidemiol. 2014 Aug;43(4):1336-9
pubmed: 24706730
Crit Care Med. 2014 Apr;42(4):868-77
pubmed: 24275513
J Am Heart Assoc. 2014 Jul 15;3(4):
pubmed: 25027018
Am J Kidney Dis. 2017 Jun;69(6):864
pubmed: 28438342
Kidney Int. 2009 Oct;76(8):893-9
pubmed: 19641480
Kidney Dis (Basel). 2021 May;7(3):167-175
pubmed: 34179112
Nat Rev Nephrol. 2018 Oct;14(10):607-625
pubmed: 30135570
PLoS One. 2020 Mar 24;15(3):e0230512
pubmed: 32208435
N Engl J Med. 2014 Jul 3;371(1):58-66
pubmed: 24988558
BMC Nephrol. 2014 Jun 18;15:93
pubmed: 24942179
Int J Nephrol. 2012;2012:361528
pubmed: 23227335
Circulation. 2009 May 12;119(18):2444-53
pubmed: 19398670
N Engl J Med. 2020 Jul 16;383(3):240-251
pubmed: 32668114
Nat Rev Nephrol. 2020 Apr;16(4):193-205
pubmed: 32051567
Clin J Am Soc Nephrol. 2009 Apr;4(4):812-9
pubmed: 19297612
Intensive Care Med. 2017 Sep;43(9):1198-1209
pubmed: 28138736
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137
pubmed: 28194657
N Engl J Med. 2022 Mar 10;386(10):964-975
pubmed: 35263520
Kidney Int. 2021 Feb;99(2):456-465
pubmed: 32707221
Anesthesiology. 2017 Jan;126(1):39-46
pubmed: 27755064
BMC Med Res Methodol. 2018 May 29;18(1):48
pubmed: 29843614
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Intensive Care Med. 2021 Aug;47(8):835-850
pubmed: 34213593
Nat Rev Nephrol. 2017 Apr;13(4):241-257
pubmed: 28239173
Am J Physiol Renal Physiol. 2001 Nov;281(5):F887-99
pubmed: 11592947
Clin Kidney J. 2022 Feb 25;15(7):1290-1299
pubmed: 35756731
PLoS Med. 2014 Feb 11;11(2):e1001601
pubmed: 24523666
Intensive Care Med. 2016 Feb;42(2):137-46
pubmed: 26626062
PLoS One. 2015 Mar 23;10(3):e0121482
pubmed: 25799318
JAMA Intern Med. 2020 Mar 1;180(3):402-410
pubmed: 31985750